Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders

Details for Australian Patent Application No. 2004288715 (hide)

Owner Celgene Corporation

Inventors Zeldis, Jerome B.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004288715

PCT Pub. Number WO2005/046594

Priority 60/518,601 06.11.03 US

Filing date 4 November 2004

Wipo publication date 26 May 2005

International Classifications

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

A61K 31/4035 (2006.01)

A61K 31/52 (2006.01)

A61K 31/522 (2006.01)

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

Event Publications

8 June 2006 PCT application entered the National Phase

  PCT publication WO2005/046594 Priority application(s): WO2005/046594

27 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004288716-Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders

2004288714-Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.